PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A GBT021601 ADME Microtracer Study in Healthy Volunteers

Phase 1

Completed

Conditions: Sickle Cell Disease

Interventions: Drug: GBT021601

First Posted Date: 2023-02-08

Last Posted Date: 2025-01-08

Lead Sponsor: Pfizer

Target Recruit Count: 9

Registration Number: NCT05718687

Locations: 🇳🇱
ICON Early Phase Clinic, LLC, Groningen, Netherlands

A Study to Assess the Safety, Effects and Palatability of Sisunatovir in Healthy Adult Participants

Phase 1

Completed

Conditions: Respiratory Syncytial Viruses

Interventions: Drug: Placebo
Drug: sisunatovir

First Posted Date: 2023-02-03

Last Posted Date: 2024-03-01

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT05712460

Locations: 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium

A Study to Learn About the Dangers Linked to Myelosuppression (Decreased Bone Marrow Function) in Breast Cancer Patients Treated With the Study Medicine Palbociclib (Pal Bow Sai Klib)

Not yet recruiting

Conditions: Breast Cancer

First Posted Date: 2023-02-02

Last Posted Date: 2023-02-02

Lead Sponsor: Pfizer

Target Recruit Count: 1300

Registration Number: NCT05709158

A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults

Phase 2

Active, not recruiting

Conditions: Human
Herpes Zoster Infection
Shingles

Interventions: Biological: Shingrix

First Posted Date: 2023-01-30

Last Posted Date: 2025-05-13

Lead Sponsor: Pfizer

Target Recruit Count: 900

Registration Number: NCT05703607

Locations: 🇺🇸
CTI Clinical Research Center, Cincinnati, Ohio, United States
🇺🇸
DM Clinical Research, Martin Diagnostic Clinic, Tomball, Texas, United States
🇺🇸
Tri-City Cardiology, Gilbert, Arizona, United States

and more 32 locations

A Study to Learn About the Effect of Avelumab First-Line Maintenance in Canadian People With Advanced Bladder Cancer

Terminated

Conditions: Bladder Tumors
Urothelial Carcinoma
Urinary Bladder Neoplasms
Bladder Cancer

Interventions: Drug: Avelumab first-line maintenance

First Posted Date: 2023-01-26

Last Posted Date: 2024-04-24

Lead Sponsor: Pfizer

Target Recruit Count: 150

Registration Number: NCT05699135

Locations: 🇨🇦
Bayshore Specialty Rx, Mississauga, Ontario, Canada

Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland

Completed

Conditions: Metastatic Castration Resistant Prostate Cancer (mCRPC)
Metastatic Castration Sensitive Prostate Cancer (mCSPC)

Interventions: Drug: degarelix
Drug: abiraterone
Drug: goserelin
Drug: enzalutamide
Drug: leuprorelin
Drug: docetaxel
Drug: triptorelin
Drug: apalutamide
Drug: cabazitaxel
Drug: Radium-223
Drug: Lutetium-177

First Posted Date: 2023-01-26

Last Posted Date: 2024-04-24

Lead Sponsor: Pfizer

Target Recruit Count: 1

Registration Number: NCT05701007

Locations: 🇫🇮
Pfizer, Helsinki, Finland

A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis.

Recruiting

Conditions: Atopic Dermatitis
Eczema

First Posted Date: 2023-01-19

Last Posted Date: 2025-05-13

Lead Sponsor: Pfizer

Target Recruit Count: 183

Registration Number: NCT05689151

Locations: 🇫🇷
CHU Amiens-Picardie - Site Nord, Amiens, Somme, France
🇫🇷
CHU Besancon - Hopital Jean Minjoz, Besancon, France
🇫🇷
Ch William Morey, Chalon Sur Saone, France

and more 7 locations

A Study to Understand the Long-term Safety and Effects of an Experimental Gene Therapy for Duchenne Muscular Dystrophy.

Phase 3

Active, not recruiting

Conditions: Duchenne Muscular Dystrophy

Interventions: Biological: fordadistrogene movaparvovec

First Posted Date: 2023-01-19

Last Posted Date: 2025-05-13

Lead Sponsor: Pfizer

Target Recruit Count: 6

Registration Number: NCT05689164

Locations: 🇺🇸
Reed Neurological Research Center, Los Angeles, California, United States
🇺🇸
UCLA Children's Heart Center, Los Angeles, California, United States
🇺🇸
UCLA Clinical Lab Services, Los Angeles, California, United States

and more 9 locations

A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Phase 4

Active, not recruiting

Conditions: Acute Lymphoblastic Leukemia

Interventions: Drug: inotuzumab ozogamicin

First Posted Date: 2023-01-17

Last Posted Date: 2025-05-22

Lead Sponsor: Pfizer

Target Recruit Count: 44

Registration Number: NCT05687032

Locations: 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
🇨🇳
Guangzhou First People's Hospital, Guangzhou, Guangdong, China

and more 12 locations

A Study to Learn How the Study Medicine (Ponsegromab) is Changed and Eliminated From Healthy Chinese Adults

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Ponsegromab

First Posted Date: 2023-01-17

Last Posted Date: 2024-09-30

Lead Sponsor: Pfizer

Target Recruit Count: 18

Registration Number: NCT05685264

Locations: 🇨🇳
HuaShan Hospital, Shanghai, Shanghai, China
🇨🇳
Huashan Hospital Fudan University, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy